PBLA Annual CFO
-$25.25 M
-$9.97 M-65.29%
31 December 2023
Summary:
As of January 23, 2025, PBLA annual cash flow from operations is -$25.25 million, with the most recent change of -$9.97 million (-65.29%) on December 31, 2023. During the last 3 years, it has fallen by -$21.39 million (-555.14%). PBLA annual CFO is now -68156.60% below its all-time high of $37.10 thousand, reached on December 31, 2012.PBLA Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
PBLA Quarterly CFO
-$2.12 M
-$1.14 M-116.11%
30 September 2024
Summary:
As of January 23, 2025, PBLA quarterly cash flow from operations is -$2.12 million, with the most recent change of -$1.14 million (-116.11%) on September 30, 2024. Over the past year, it has increased by +$960.00 thousand (+31.17%). PBLA quarterly CFO is now -2070.26% below its all-time high of $107.60 thousand, reached on June 30, 2012.PBLA Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
PBLA TTM CFO
-$15.57 M
+$4.56 M+22.64%
30 September 2024
Summary:
As of January 23, 2025, PBLA TTM cash flow from operations is -$15.57 million, with the most recent change of +$4.56 million (+22.64%) on September 30, 2024. Over the past year, it has increased by +$9.68 million (+38.32%). PBLA TTM CFO is now -11879.88% below its all-time high of $132.20 thousand, reached on June 30, 2014.PBLA TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
PBLA Cash From Operations Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -65.3% | +31.2% | +38.3% |
| 3 y3 years | -555.1% | +78.3% | +24.2% |
| 5 y5 years | -957.8% | +78.3% | +24.2% |
PBLA Cash From Operations High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -248.5% | at low | -116.1% | +78.3% | -115.0% | +42.7% |
| 5 y | 5-year | -821.8% | at low | -177.1% | +78.3% | -468.6% | +42.7% |
| alltime | all time | <-9999.0% | at low | -2070.3% | +78.3% | <-9999.0% | +42.7% |
Panbela Therapeutics Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$2.12 M(+116.1%) | -$15.57 M(-22.6%) |
| June 2024 | - | -$981.00 K(-89.6%) | -$20.13 M(-19.1%) |
| Mar 2024 | - | -$9.39 M(+204.9%) | -$24.89 M(-1.4%) |
| Dec 2023 | -$25.25 M(+65.3%) | -$3.08 M(-53.9%) | -$25.25 M(-7.1%) |
| Sept 2023 | - | -$6.68 M(+16.3%) | -$27.17 M(+23.0%) |
| June 2023 | - | -$5.74 M(-41.1%) | -$22.09 M(+7.5%) |
| Mar 2023 | - | -$9.75 M(+94.9%) | -$20.54 M(+34.5%) |
| Dec 2022 | -$15.28 M(+110.8%) | -$5.00 M(+214.1%) | -$15.28 M(+22.2%) |
| Sept 2022 | - | -$1.59 M(-62.0%) | -$12.50 M(+1.9%) |
| June 2022 | - | -$4.20 M(-6.4%) | -$12.27 M(+25.6%) |
| Mar 2022 | - | -$4.48 M(+101.2%) | -$9.76 M(+34.8%) |
| Dec 2021 | -$7.25 M(+88.0%) | -$2.23 M(+63.9%) | -$7.25 M(+18.2%) |
| Sept 2021 | - | -$1.36 M(-19.7%) | -$6.13 M(+10.7%) |
| June 2021 | - | -$1.69 M(-13.8%) | -$5.54 M(+17.8%) |
| Mar 2021 | - | -$1.97 M(+76.5%) | -$4.70 M(+21.9%) |
| Dec 2020 | -$3.85 M(+40.7%) | -$1.11 M(+45.5%) | -$3.85 M(+6.7%) |
| Sept 2020 | - | -$765.00 K(-10.6%) | -$3.61 M(+9.5%) |
| June 2020 | - | -$856.00 K(-23.6%) | -$3.30 M(+7.3%) |
| Mar 2020 | - | -$1.12 M(+28.4%) | -$3.08 M(+12.3%) |
| Dec 2019 | -$2.74 M(+14.7%) | -$872.00 K(+92.5%) | -$2.74 M(+35.0%) |
| Sept 2019 | - | -$453.00 K(-28.2%) | -$2.03 M(-8.4%) |
| June 2019 | - | -$631.00 K(-19.4%) | -$2.22 M(-14.2%) |
| Mar 2019 | - | -$783.00 K(+383.3%) | -$2.58 M(+8.2%) |
| Dec 2018 | -$2.39 M | -$162.00 K(-74.7%) | -$2.39 M(-20.6%) |
| Sept 2018 | - | -$640.00 K(-35.8%) | -$3.01 M(+14.4%) |
| June 2018 | - | -$997.00 K(+69.6%) | -$2.63 M(-9.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2018 | - | -$588.00 K(-24.9%) | -$2.92 M(-14.2%) |
| Dec 2017 | -$3.40 M(+41.9%) | -$783.00 K(+200.0%) | -$3.40 M(-1.3%) |
| Sept 2017 | - | -$261.00 K(-79.7%) | -$3.45 M(-16.4%) |
| June 2017 | - | -$1.29 M(+20.0%) | -$4.13 M(+40.9%) |
| Mar 2017 | - | -$1.07 M(+29.5%) | -$2.93 M(+22.1%) |
| Dec 2016 | -$2.40 M(-38.5%) | -$828.00 K(-11.8%) | -$2.40 M(-2.0%) |
| Sept 2016 | - | -$939.00 K(+955.1%) | -$2.45 M(+2.6%) |
| June 2016 | - | -$89.00 K(-83.6%) | -$2.39 M(-32.4%) |
| Mar 2016 | - | -$542.00 K(-38.3%) | -$3.53 M(-9.4%) |
| Dec 2015 | -$3.90 M(+16.6%) | -$878.00 K(0.0%) | -$3.90 M(-6.9%) |
| Sept 2015 | - | -$878.00 K(-28.8%) | -$4.19 M(-24.1%) |
| June 2015 | - | -$1.23 M(+36.1%) | -$5.52 M(+29.3%) |
| Mar 2015 | - | -$907.00 K(-22.4%) | -$4.27 M(+27.6%) |
| Dec 2014 | -$3.34 M(+9343.5%) | -$1.17 M(-47.0%) | -$3.34 M(+61.4%) |
| Sept 2014 | - | -$2.21 M(<-9900.0%) | -$2.07 M(-1666.9%) |
| June 2014 | - | $16.30 K(-0.6%) | $132.20 K(+92.7%) |
| Mar 2014 | - | $16.40 K(-84.0%) | $68.60 K(-294.3%) |
| Dec 2013 | -$35.40 K(-195.4%) | $102.50 K(-3516.7%) | -$35.30 K(-79.4%) |
| Sept 2013 | - | -$3000.00(-93.7%) | -$171.60 K(-3.3%) |
| June 2013 | - | -$47.30 K(-45.9%) | -$177.50 K(+685.4%) |
| Mar 2013 | - | -$87.50 K(+158.9%) | -$22.60 K(-160.9%) |
| Dec 2012 | $37.10 K(-150.8%) | -$33.80 K(+279.8%) | $37.10 K(-47.7%) |
| Sept 2012 | - | -$8900.00(-108.3%) | $70.90 K(-11.2%) |
| June 2012 | - | $107.60 K(-487.1%) | $79.80 K(-387.1%) |
| Mar 2012 | - | -$27.80 K | -$27.80 K |
| Dec 2011 | -$73.00 K | - | - |
FAQ
- What is Panbela Therapeutics annual cash flow from operations?
- What is the all time high annual CFO for Panbela Therapeutics?
- What is Panbela Therapeutics annual CFO year-on-year change?
- What is Panbela Therapeutics quarterly cash flow from operations?
- What is the all time high quarterly CFO for Panbela Therapeutics?
- What is Panbela Therapeutics quarterly CFO year-on-year change?
- What is Panbela Therapeutics TTM cash flow from operations?
- What is the all time high TTM CFO for Panbela Therapeutics?
- What is Panbela Therapeutics TTM CFO year-on-year change?
What is Panbela Therapeutics annual cash flow from operations?
The current annual CFO of PBLA is -$25.25 M
What is the all time high annual CFO for Panbela Therapeutics?
Panbela Therapeutics all-time high annual cash flow from operations is $37.10 K
What is Panbela Therapeutics annual CFO year-on-year change?
Over the past year, PBLA annual cash flow from operations has changed by -$9.97 M (-65.29%)
What is Panbela Therapeutics quarterly cash flow from operations?
The current quarterly CFO of PBLA is -$2.12 M
What is the all time high quarterly CFO for Panbela Therapeutics?
Panbela Therapeutics all-time high quarterly cash flow from operations is $107.60 K
What is Panbela Therapeutics quarterly CFO year-on-year change?
Over the past year, PBLA quarterly cash flow from operations has changed by +$960.00 K (+31.17%)
What is Panbela Therapeutics TTM cash flow from operations?
The current TTM CFO of PBLA is -$15.57 M
What is the all time high TTM CFO for Panbela Therapeutics?
Panbela Therapeutics all-time high TTM cash flow from operations is $132.20 K
What is Panbela Therapeutics TTM CFO year-on-year change?
Over the past year, PBLA TTM cash flow from operations has changed by +$9.68 M (+38.32%)